Denali Therapeutics (NASDAQ:DNLI) Posts Quarterly Earnings Results, Misses Expectations By $0.03 EPS

Denali Therapeutics (NASDAQ:DNLI) posted its quarterly earnings data on Wednesday. The company reported ($0.63) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.03), Briefing.com reports. During the same period in the previous year, the firm posted ($0.72) earnings per share.

Denali Therapeutics Trading Up 1.6 %

NASDAQ:DNLI traded up $0.46 on Friday, hitting $30.06. 107,778 shares of the stock were exchanged, compared to its average volume of 1,068,161. The stock has a fifty day moving average of $27.67 and a 200-day moving average of $23.40. The stock has a market cap of $4.30 billion, a PE ratio of -10.39 and a beta of 1.40. Denali Therapeutics has a fifty-two week low of $14.56 and a fifty-two week high of $32.13.

Insider Activity

In related news, Director Steve E. Krognes sold 30,000 shares of the stock in a transaction that occurred on Monday, September 30th. The shares were sold at an average price of $29.03, for a total transaction of $870,900.00. Following the completion of the sale, the director now owns 29,096 shares of the company’s stock, valued at approximately $844,656.88. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, CEO Ryan J. Watts sold 40,000 shares of Denali Therapeutics stock in a transaction on Friday, October 18th. The shares were sold at an average price of $27.69, for a total transaction of $1,107,600.00. Following the transaction, the chief executive officer now owns 235,807 shares in the company, valued at approximately $6,529,495.83. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Steve E. Krognes sold 30,000 shares of the business’s stock in a transaction dated Monday, September 30th. The stock was sold at an average price of $29.03, for a total value of $870,900.00. Following the transaction, the director now owns 29,096 shares in the company, valued at approximately $844,656.88. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 7.90% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on DNLI shares. Raymond James reiterated a “market perform” rating on shares of Denali Therapeutics in a report on Thursday, October 10th. Cantor Fitzgerald cut shares of Denali Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Monday, October 7th. JPMorgan Chase & Co. reduced their price target on Denali Therapeutics from $29.00 to $28.00 and set an “overweight” rating on the stock in a research note on Friday, October 11th. HC Wainwright reaffirmed a “buy” rating and issued a $90.00 price objective on shares of Denali Therapeutics in a research report on Thursday. Finally, Wedbush reduced their target price on Denali Therapeutics from $30.00 to $26.00 and set an “outperform” rating on the stock in a research report on Friday, August 2nd. Three analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, Denali Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $38.90.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.